JP2008543813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543813A5 JP2008543813A5 JP2008516325A JP2008516325A JP2008543813A5 JP 2008543813 A5 JP2008543813 A5 JP 2008543813A5 JP 2008516325 A JP2008516325 A JP 2008516325A JP 2008516325 A JP2008516325 A JP 2008516325A JP 2008543813 A5 JP2008543813 A5 JP 2008543813A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- prevention
- treatment
- nervous system
- central nervous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501383 | 2005-06-17 | ||
| US70652305P | 2005-08-09 | 2005-08-09 | |
| PCT/EP2006/063249 WO2006134150A1 (en) | 2005-06-17 | 2006-06-15 | Benzofuranyl derivatives as 5-ht6-receptor inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008543813A JP2008543813A (ja) | 2008-12-04 |
| JP2008543813A5 true JP2008543813A5 (cg-RX-API-DMAC7.html) | 2009-07-23 |
Family
ID=36659956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008516325A Withdrawn JP2008543813A (ja) | 2005-06-17 | 2006-06-15 | ５−ｈｔ６−受容体阻害剤としてのベンゾフラニル誘導体 |
Country Status (18)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| CN103880797B (zh) * | 2014-03-26 | 2015-12-02 | 沈阳大学 | 苯并呋喃类化合物及其医药用途 |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| EP4526469A1 (en) | 2022-05-16 | 2025-03-26 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| ATE319683T1 (de) | 1998-12-11 | 2006-03-15 | Univ Virginia Commonwealth | Selektive 5-ht 6-rezeptor-liganden |
| WO2002100822A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| RS44204A (sr) * | 2001-11-22 | 2007-06-04 | Biovitrum Ab., | Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1 |
| NZ552282A (en) | 2002-06-20 | 2008-07-31 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
| US7943639B2 (en) * | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
| SE0303480D0 (sv) * | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
-
2006
- 2006-06-05 US US11/447,524 patent/US7582767B2/en not_active Expired - Fee Related
- 2006-06-15 ZA ZA200710468A patent/ZA200710468B/xx unknown
- 2006-06-15 WO PCT/EP2006/063249 patent/WO2006134150A1/en not_active Ceased
- 2006-06-15 AU AU2006259082A patent/AU2006259082B2/en not_active Ceased
- 2006-06-15 JP JP2008516325A patent/JP2008543813A/ja not_active Withdrawn
- 2006-06-15 DE DE602006008002T patent/DE602006008002D1/de active Active
- 2006-06-15 CA CA002610383A patent/CA2610383A1/en not_active Abandoned
- 2006-06-15 ES ES06763743T patent/ES2330145T3/es active Active
- 2006-06-15 DK DK06763743T patent/DK1896460T3/da active
- 2006-06-15 BR BRPI0612746-0A patent/BRPI0612746A2/pt not_active IP Right Cessation
- 2006-06-15 EP EP06763743A patent/EP1896460B1/en not_active Not-in-force
- 2006-06-15 KR KR1020087001242A patent/KR20080017482A/ko not_active Ceased
- 2006-06-15 EA EA200800071A patent/EA015671B1/ru not_active IP Right Cessation
- 2006-06-15 NZ NZ563510A patent/NZ563510A/en not_active IP Right Cessation
- 2006-06-15 MX MX2007015988A patent/MX2007015988A/es active IP Right Grant
- 2006-06-15 CN CN2006800201432A patent/CN101193885B/zh not_active Expired - Fee Related
-
2007
- 2007-11-22 IL IL187575A patent/IL187575A/en not_active IP Right Cessation
-
2008
- 2008-01-17 NO NO20080354A patent/NO20080354L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183410A5 (cg-RX-API-DMAC7.html) | ||
| JP2004531516A5 (cg-RX-API-DMAC7.html) | ||
| JP2010535252A5 (cg-RX-API-DMAC7.html) | ||
| RU2005135958A (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5, 8, 14-триазатетрацикло[10.3.1.02,11.04,9]-гексадека-2( 11 ), 3,5,7,9-пентаена | |
| JP2009504748A5 (cg-RX-API-DMAC7.html) | ||
| WO2007093624A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| JP2013545730A5 (cg-RX-API-DMAC7.html) | ||
| JP2006503850A5 (cg-RX-API-DMAC7.html) | ||
| JP2010511701A5 (cg-RX-API-DMAC7.html) | ||
| US20110224196A1 (en) | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent | |
| JP2011516417A5 (cg-RX-API-DMAC7.html) | ||
| JP2020514316A5 (cg-RX-API-DMAC7.html) | ||
| JP2020512337A5 (cg-RX-API-DMAC7.html) | ||
| WO2006119958A2 (en) | Use of flibanserin in the treatment of chronic pain | |
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| JP2008539267A5 (cg-RX-API-DMAC7.html) | ||
| JP2003519228A5 (cg-RX-API-DMAC7.html) | ||
| US20240139224A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| JP2002535370A5 (cg-RX-API-DMAC7.html) | ||
| ES2426008T5 (es) | Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas | |
| EP1621198A3 (en) | Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists | |
| JP2008543813A5 (cg-RX-API-DMAC7.html) | ||
| JP2010500284A5 (cg-RX-API-DMAC7.html) | ||
| RU2004131214A (ru) | Способы лечения когнитивных расстройств |